Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 3/20 | 0.66 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.51 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.51 |
| ▸ | HTR1A | P08908 | 4/20 | 0.51 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.50 |
| ▸ | HTR2C | P28335 | 2/20 | 0.48 |
| ▸ | HTR2B | P41595 | 2/20 | 0.48 |
| ▸ | IKBKB | O14920 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.46 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.45 |
| ▸ | PRKACA | P17612 | 1/20 | 0.45 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.45 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.45 |
| ▸ | PRKG1 | Q13976 | 1/20 | 0.45 |
| ▸ | PKN1 | Q16512 | 1/20 | 0.45 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.45 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.45 |
| ▸ | CDC42BPA | Q5VT25 | 1/20 | 0.45 |
| ▸ | Q6ZSR9 | Q6ZSR9 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2776364 | 0.98 | HRH1 (0.63) | HRH1SLC6A2SLC6A3HTR1ASLC6A4 | |
| Hydrochloric Acid SCHEMBL23410278 | 0.96 | HRH1 (0.61) | HRH1SLC6A2SLC6A3HTR1ASLC6A4 | |
| SCHEMBL14431595 | 0.94 | HRH1 (0.59) | HRH1SLC6A2SLC6A3HTR1ASLC6A4 | |
| SCHEMBL19838848 | 0.93 | HRH1 (0.58) | HRH1SLC6A2SLC6A3HTR1ASLC6A4 | |
| SCHEMBL4125994 | 0.89 | HTR2C (0.59) | HRH1SLC6A2SLC6A3HTR1ASLC6A4 | |
| SCHEMBL4700578 | 0.89 | HTR2C (0.59) | HRH1SLC6A2SLC6A3HTR1ASLC6A4 | |
| SCHEMBL3380245 | 0.89 | HTR2C (0.59) | HRH1SLC6A2SLC6A3HTR1ASLC6A4 | |
| Hydrochloric Acid SCHEMBL28313667 | 0.87 | HTR2C (0.58) | HRH1SLC6A2SLC6A3HTR1ASLC6A4 | |
| Hydrochloric Acid SCHEMBL28313668 | 0.87 | HTR2C (0.58) | HRH1SLC6A2SLC6A3HTR1ASLC6A4 | |
| SCHEMBL30045 | 0.85 | EPHX2 (0.57) | HRH1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 256 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9951040-B2 | 1,3,5 -triazine based PI3K inhibitors as anticancer agents and a process for the preparation thereof | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2018-04-24 | — | — | US | claimed |
| US-20170342049-A1 | NOVEL 1,3,5 -TRIAZINE BASED PI3K INHIBITORS AS ANTICANCER AGENTS AND A PROCESS FOR THE PREPARATION THEREOF | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2017-11-30 | — | — | US | claimed |
| EP-3221307-A1 | NOVEL 1,3,5 -TRIAZINE BASED PI3K INHIBITORS AS ANTICANCER AGENTS AND A PROCESS FOR THE PREPARATION THEREOF | Council of Scientific and Industrial Research (IN) | 2017-09-27 | — | — | EP | claimed |
| WO-2016079760-A1 | NOVEL 1,3,5 -TRIAZINE BASED PI3K INHIBITORS AS ANTICANCER AGENTS AND A PROCESS FOR THE PREPARATION THEREOF | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2016-05-26 | — | — | WO | claimed |
| WO-2025137146-A1 | SUBSTITUTED HETEROARYL ANALOGS AND USES THEREOF FOR THE TREATMENT OF HIV-ASSOCIATED NEUROCOGNITIVE DISORDERS | MOUKHA CHAFIQ OMAR (US) | 2025-06-26 | — | — | WO | disclosed |
| CN-108456204-B | Benzothiazine derivative, and preparation method and application thereof | 四川大学 | 2023-05-26 | — | — | CN | disclosed |
| US-20230082430-A1 | TRICYCLIC DEGRADERS OF IKAROS AND AIOLOS | C4 THERAPEUTICS, INC. (US) | 2023-03-16 | — | — | US | disclosed |
| US-20230062100-A1 | SUBSTITUTED AMINOQUINOLONES AS DGKALPHA INHIBITORS FOR IMMUNE ACTIVATION | BAYER AKTIENGESELLSCHAFT (DE) | 2023-03-02 | — | — | US | disclosed |
| US-20230014173-A1 | Antibacterial Compounds | JANSSEN SCIENCES IRELAND UC (IE) | 2023-01-19 | — | — | US | disclosed |
| CN-109689650-B | Benzamide derivatives P2X7 receptor antagonists containing phenoxypiperidine or benzyloxypiperidine and thiazole | 阿克萨姆股份公司 | 2022-11-25 | — | — | CN | disclosed |
| CN-115210225-A | Substituted aminoquinolones as immuno-activated DGKALPHA inhibitors | 拜耳公司 | 2022-10-18 | — | — | CN | disclosed |
| EP-4065570-A1 | SUBSTITUTED AMINOQUINOLONES AS DGKALPHA INHIBITORS FOR IMMUNE ACTIVATION | Bayer Aktiengesellschaft (DE) | 2022-10-05 | — | — | EP | disclosed |
| EP-0635505-A1 | 4-Aryloxy- and 4-arylthiopiperidine derivatives | MERCK PATENT GmbH (DE) | 1995-01-25 | — | — | EP | disclosed |
| EP-0557526-A1 | PYRROLOAZEPINE COMPOUND | SUNTORY LIMITED (JP) | 1993-09-01 | — | — | EP | disclosed |
| US-5206239-A | Cardiovascular disorders | SUNTORY LIMITED (JP) | 1993-04-27 | — | — | US | disclosed |
| EP-0480794-A1 | 2-Aminopyrimidine-4-carboxamide derivatives, their preparation and therapeutic use | SYNTHELABO (FR) | 1992-04-15 | — | — | EP | disclosed |
| EP-0441349-A1 | Pyrroloazepine derivatives | SUNTORY LIMITED (JP) | 1991-08-14 | — | — | EP | disclosed |
| EP-0158283-A2 | Substituted 1-aminoalkylamino-4-aryloxypiperidines, a process for their preparation, intermediates thereof, and their use as medicaments | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1985-10-16 | — | — | EP | disclosed |
| US-4518713-A | Analgesic substituted-1-aminoalkylamino-4-aryloxypiperidines | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1985-05-21 | — | — | US | disclosed |
| US-4031221-A | ANALGESICS, TRANQUILIZERS, INDOLE COMPOUNDS | AMERICAN HOECHST CORPORATION (US) | 1977-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230062100-A1 | SUBSTITUTED AMINOQUINOLONES AS DGKALPHA INHIBITORS FOR IMMUNE ACTIVATION | DGKK, DGKG, DGKA | HRH1 326/4885SLC6A2 4689/4885SLC6A3 4567/4885 |
| US-20230082430-A1 | TRICYCLIC DEGRADERS OF IKAROS AND AIOLOS | CRBN, IKZF1, IKZF3 | HRH1 4371/4885SLC6A2 4825/4885SLC6A3 4688/4885 |
| US-20230014173-A1 | Antibacterial Compounds | FDPS, SQOR, NDUFS3 | HRH1 2270/4885SLC6A2 3791/4885SLC6A3 4128/4885 |
| US-20170342049-A1 | NOVEL 1,3,5 -TRIAZINE BASED PI3K INHIBITORS AS ANTICANCER AGENTS AND A PROCESS FOR THE PREPARATION THEREOF | PIK3CA, PIK3R5, PIK3CD | HRH1 3298/4885SLC6A2 4708/4885SLC6A3 4518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.